음성 증상이 주된 조현병 환자에서 Aripiprazole의 효과에 대한 52주의 전향적 연구 = Efficacy of Aripiprazole in Korean Schizophrenic Patients with Prominent Negative Symptoms : A 52-Week, Prospective, Open-Label Study

다국어 초록 (Multilingual Abstract)

p＜.0001), and 41.03% of patients appeared to respond according to CGI-I.
Conclusion：Aripiprazole may be as much efficacious against negative symptoms as positive symptoms in schizophrenia. This suggests the possibility clinicians can consider aripiprazole as a drug of choice in the chronic schizophrenic patients with prominent negative symptoms before trying switching other antipsychotics with clozapine.

국문 초록 (Abstract)

본 연구는 aripiprazole이 만성 조현병 환자의 선택 약제로 사용될 수 있는 작은 가능성을 제시하였다고 평가할 수 있겠다. 많은 종류의 항정신병약물이 조현병의 치료를 위해 쓰여지고 있는 현 상황에서, 병의 경과 상 다양한 시점에 놓인 각각의 환자군에 대한 보다 많은 종류의 항정신병약물 효과에 대한 비교 연구가 축적된다면, 임상의사의 약물 선택에 대한 시행착오가 지금보다는 줄어들 수 있을 것이다.

다국어 초록 (Multilingual Abstract)

Objectives：This study was done to evaluate the efficacy of aripiprazole in the schizophrenic patients with prominent negative symptoms.
Methods：This study was a prospective, multicenter, single-group, 52-week open study of patients with schizophrenia, schizophreniform disorder and schizoaffective disorder. A total of 300 Korean patients participated in the study. Among them, 39 patients with prominent negative symptoms were initially administered 15mg/day of aripiprazole for the first 2 weeks, and then treated with 10-30mg/day. The efficacy measures included the Positive and Negative Syndrome Scale(PANSS) total, positive and negative subscale scores, the Clinical Global Impression-Severity of Illness(CGI-S), and the CGI-Global improvements(CGI-I).
Results：The significant improvements were observed in all 3 PANSS parameters

다국어 초록 (Multilingual Abstract)

total(-35.72

다국어 초록 (Multilingual Abstract)

p＜.0001), positive subscale(-7.41

다국어 초록 (Multilingual Abstract)

p＜.0001), and negative subscale scores(-11.56

다국어 초록 (Multilingual Abstract)

p＜.0001). The difference between positive and negative subscale scores was significantly decreased from baseline to week 52. CGI-S was also decreased (-1.67

목차 (Table of Contents)

• 서론
• 방법
• 결과
• 고찰
• 요약
• 참고문헌

참고문헌 (Reference)

1 박혜윤, "정신분열병 환자에서 52주간의 Aripiprazole 치료가 사회적 기능에 미치는 영향" 대한정신약물학회 19 (19): 256-265, 2008

2 Lee HY, "Trial of aripiprazole in the treatment of first-episode schizophrenia" 64 (64): 38-43, 2010

3 Kay SR, "The positive and negative syndrome scale(PANSS)for schizophrenia" 13 : 261-276, 1987

4 Berman RM, "The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder:A multicenter,randomized,double-blind,placebo-controlled study" 68 : 843-853, 2007

5 Jordan S, "The antipsychotic aripiprazole is a potent,partial agonist at the human 5-HT1A receptor" 441 : 137-140, 2002

6 Kane JM, "Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks" 95 : 143-150, 2007

7 Leucht S, "Second-generation versus firstgeneration antipsychotic drugs for schizophrenia:A meta-analysis" 373 : 31-41, 2009

8 McGorry PD, "Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms" 59 : 921-928, 2002

9 Pae CU, "Predictors of early worsening after switch to aripiprazole:a randomized,controlled,open-label study" 30 : 187-193, 2010

10 Bell M, "Object relations deficits in subtypes of schizophrenia" 48 : 433-444, 1992

11 Stip E, "Novel antipsychotics:Issues and controversies.Typicality of atypical antipsychotics" 25 : 137-153, 2000

12 Lawler CP, "Interactions of the novel anti natupsychotic aripiprazole(OPC-14597)with dopamine and serotonin receptor subtypes" 20 : 612-627, 1999

13 Kasper S, "Efficacy and safety of aripiprazole vs.haloperidol for long-term maintenance treatment following acute relapse of schizophrenia" 6 : 325-337, 2003

14 Chan HY, "Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control:a randomized trial" 68 : 29-36, 2007

15 Kane JM, "Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder" 63 : 763-771, 2002

16 Goldstein M, "Dopaminergic mechanisms in the pathogenesis of schizophrenia" 6 : 2413-2421, 1992

17 American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th ed" APA 2000

18 Potkin SG, "Aripiprazole,an antipsychotic with a novel mechanism of action,and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder" 60 : 681-690, 2003

19 Burris KD, "Aripiprazole,a novel antipsychotic,is a highaffinity partial agonist at human dopamine D2 receptors" 302 : 381-389, 2002

20 Ramaswamy S, "Aripiprazole possibly worsens psychosis" 19 : 45-48, 2004

21 Pigott TA, "Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia:A placebocontrolled 26-week study" 64 : 1048-1056, 2003

22 de Oliveira IR, "Aripiprazole for patients with schizophrenia and schizoaffective disorder:an open-label,randomized,study versus haloperidol" 14 : 93-102, 2009

23 Keck PE Jr, "Aripiprazole Study Group.Aripiprazole monotherapy for maintenance therapy in bipolar I disorder:A 100-week,doubleblind study versus placebo" 68 : 1480-1491, 2007

24 Anghelescu I, "Are new drugs for schizo phrenia better than old ones" 373 : 1249-, 2009

25 Bellack AS, "An analysis of social competence in schizophrenia" 156 : 809-818, 1990

26 Kwon JS, "APLUS study group.Long-term efficacy and safety of aripiprazole in patients with schizophrenia,schizophreniform disorder,or schizoaffective disorder:26-week prospective study" 63 : 73-81, 2009

27 Saha S, "A systematic review of the prevalence of schizophrenia" 2 : e141-, 2005

28 Tandon R, "A prospective,multicenter,randomized,parallel-group,open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice:Broad Effectiveness Trial With Aripiprazole(BETA)" 84 : 77-89, 2006

29 Kikuchi T, "7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2(1H)-quinolinone(OPC-14597),a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity" 274 : 329-336, 1995